Focus on Myeloma (October 2015, Volume 1, Issue 10.1)

October 2015 Special Edition

Volume 1, Issue 10.1

This special issue of ASH Clinical News features updates in the world of multiple myeloma, including treatment options, advancements in understanding the disease, and looking ahead to the landscape of care.

Table of Contents

Focus on Myeloma

The Present and Future Multiple Myeloma Landscape

Thursday, October 1st, 2015
The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...

Focus on Myeloma

Clinical Trial Updates

Thursday, October 1st, 2015
A look at the ongoing clinical trials in multiple myeloma. PHASE III TRIALS A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo...

Focus on Myeloma

Recently Approved Agents

Thursday, October 1st, 2015
In 2015, the U.S. Food and Drug Administration approved two agents for the treatment of patients with multiple myeloma (MM): the HDAC inhibitor panobinostat...

Focus on Myeloma

Carfilzomib Bests Bortezomib in Relapsed Multiple Myeloma

Thursday, October 1st, 2015
Results from the phase III, open-label, multicenter ENDEAVOR study support the use of the proteasome inhibitor, carfilzomib, in combination with dexamethasone in patients with...

Pinpointing the Mechanisms that Transform MGUS into Myeloma

Thursday, October 1st, 2015
A molecular study of monoclonal gammopathy of undetermined significance (MGUS) and myeloma has provided new insight into the biology of myeloma, finding that MGUS...

IMWG Revises International Staging System for Multiple Myeloma

Thursday, October 1st, 2015
At this year’s International Myeloma Working Group (IMWG) Summit, this large team of myeloma experts released a revised International Staging System (R-ISS) for newly...

Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

Thursday, October 1st, 2015
Elotuzumab, a novel anti-SLAMF7 monoclonal antibody, extended multiple myeloma (MM) patients’ duration of remission by about five months, on average, compared with standard treatment...

Safety Profile of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients

Thursday, October 1st, 2015
For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, as with other monoclonal antibody therapies, management of infusion-related reactions (IRRs)...

Safety and Tolerability of MOR202 in Relapsed/Refractory Myeloma Patients

Thursday, October 1st, 2015
A recent phase I/IIa study evaluated the safety and efficacy of MOR202, a human monoclonal anti-CD38 antibody, in adult patients with relapsed/refractory multiple myeloma...

Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients

Thursday, October 1st, 2015
Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...

SHARE